Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of the Vericheck ddPCR™ Empty-Full Capsid Kit ...
In February 2026, Bio-Rad Laboratories reported fourth-quarter 2025 sales of US$693.2 million and net income of US$720 million, marking a return to profitability after a prior-year loss, alongside ...
New research demonstrating the pivotal role of Bio-Rad’s Droplet Digital PCR (ddPCR™) technology in detecting cell-free DNA and RNA biomarkers in cancer liquid biopsies has been presented at the ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the recent launch of the Vericheck ddPCR™ Replication ...
Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately ...
Bio-Rad (CA, USA), a clinical diagnostics products company, has launched a new ddPCR kit designed to assess AAV vector quality for gene therapy development. Vericheck ddPCR Empty-Full Capsid Kit can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results